Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Japan Selects JN.1 Substrains for COVID Vaccines in 2026-2027 Season
A Japanese health ministry panel on May 26 agreed to adopt JN.1 substrains for the antigen composition of COVID-19 vaccines to be used in the national immunization program during the 2026/2027 season. The selected antigens are monovalent LP.8.1 as well…
To read the full story
Related Article
- Japan Picks 5 COVID Vaccines for NIP Use from October
September 3, 2026
- Takeda’s XFG-Targeted COVID Jab Approved in Japan
August 27, 2026
- Meiji Wins Japan Approval for NB.1.8.1-Adapted COVID Vaccine
August 27, 2026
- Japan Expects Flu Vaccine Supply of 51.9 Million Doses for 2026-27
August 27, 2026
- Moderna’s mNEXSPIKE Grabs Japan Approval for XFG Variant
August 20, 2026
- Pfizer, BioNTech Win Japan Nod for XFG-Adapted COVID Vaccines
August 18, 2026
- Takeda Files XFG-Adapted COVID Vaccine in Japan
June 29, 2026
- Japan Selects JN.1 Substrains for COVID Vaccines in 2025-2026 Season
May 30, 2025
REGULATORY
- MHLW Seeks at Least 275 Billion Yen to Shore Up Drug Supplies
September 7, 2026
- Yaz, Actemra Indications Deemed High-Need by MHLW Panel
September 7, 2026
- Minister Defends Scope of Low-Income Exemption for OTC-Like Drug Charge
September 7, 2026
- LDP Panel Chief Calls for Earlier CGP Coverage in Cancer Care
September 4, 2026
- Japan to Revisit Handling of Steroid Creams under OTC-Like Drug Charge
September 4, 2026
Japan has entered a third straight year of wage hikes averaging 5%, but the pharmaceutical industry is struggling to keep…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…